Bio-Inequivalence Is Not Simply Failure To Show Bioequivalence, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will propose standards for demonstrating bio-inequivalence at the April 14 meeting of the Pharmaceutical Science Advisory Committee. Topical bioequivalence and bioequivalence of highly variable drugs will be discussed as well.
You may also be interested in...
Highly Variable Drug Bioequivalence Could Be Shown Through Reference Scaling, Cmte. Suggests
Reference scaling may be an interim solution to demonstrating bioequivalence for highly variable drug products; in the future, FDA should create a decision tree that allows the bioequivalence range to adjust with the drug's variability, FDA's Pharmaceutical Science Advisory Committee says.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).